In a press release by NetworkNewsAudio, Lexaria Bioscience Corp (OTCMKTS:LXRP) has announced that their subsidiary Lexaria Nicotine LLC has executed a definitive agreement that will allow it to pursue oral and reduced risk nicotine innovations through the DehydraTECH™ technology. This is a move of leveling the playing field against big Bioscience companies.
The definitive investment agreement
Lexaria’s DehydraTECH™ technology is seen as a game changer since it enhances the performance of beneficial ingestible compounds in categories that include speed of action, smell, taste, and bioavailability. The definitive agreement outlines a breakthrough research and development program carried by Laxaria in the delivery of oral forms of nicotine through their novel technology.
Lexaria nicotine will receive funding through several private financing phases, and in return, the parent will get minority equity interest of the company as well as some DehydraTECH™ licensing rights.
Chris Bunka, the Lexaria Bioscience CEO, stated that the company was proud of securing funding for the development of DehydraTECH™ technology as well as potential commercialization of the technology for oral nicotine production.
Why Lexaria Bioscience?
Although Laxaria is a relatively small company, they got chosen because of their proprietary DehydraTECH™ technology. The DehydraTECH™ technology is proven as it has shown the ability to conceal the unpleasant flavors as well as accelerate the delivery of orally ingested nicotine in previous studies. For instance, it has been demonstrated that one can satisfy nicotine craving through a cup of coffee.
Equally in addition to ensuring bioactive substances are pleasant to consume the technology has proved that it makes them effective once ingested. DehydraTECH™ accelerates and increases bioactive absorption in edible format thus ensuring there is a healthier way of increasing uptake as an alternative to smoking.
John Docherty, Laxaria Bioscience’s president, states that the company has severally demonstrated the powerful impact of their DehydraTECH™ technology in enhancing speed and palatability of orally consumed bioactive ingredients such as nicotine. He adds that their laboratory research on oral nicotine formulations up to date has been encouraging and the company is excited to advance the clinical phase of their research and development program together with their new partnership with the aim of full commercialization.